All results
8 results for randomized double blind placebo controlled study assess efficacy safety and
-
Armata
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…
- Ages
- 18 Years - N/A
- Sexes
- All
-
diSArm
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…
- Ages
- 18 Years - N/A
- Sexes
- All
-
MOM-M281-006
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA). The study consists…
- Ages
- 18 Years - N/A
- Sexes
- All
-
United therapeutics 301
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3) This is a multi-part study comprising of the original Phase 2b study (active, no…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Vasomune AV001-004
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…
- Ages
- 18 Years - N/A
- Sexes
- All
-
RECOVER VITAL
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community…
- Ages
- 18 Years - N/A
- Sexes
- All